Gastroenteropancreatic Neuroendocrine Tumors

The addition of a radioligand therapy to first-line treatment with long-acting octreotide prolonged PFS for patients with gastroenteropancreatic neuroendocrine tumors, according to the agent’s manufacturer.

The FDA granted fast track designation to ITM-11 for treatment of gastroenteropancreatic neuroendocrine tumors.

Nintedanib appeared safe and effective for the treatment of advanced nonpancreatic neuroendocrine tumors, according to results of a phase 2 study published in Cancer.